These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14741259)

  • 21. 3-Aryl-4-aryloyl-1-(1H-imidazol-5-yl)methylpyrrole, a novel class of farnesyltransferase inhibitors.
    Lee H; Lee J; Shin Y; Jung W; Kim JH; Park K; Ro S; Chung HH; Koh JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2963-5. PubMed ID: 11677136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential.
    Tanaka R; Rubio A; Harn NK; Gernert D; Grese TA; Eishima J; Hara M; Yoda N; Ohashi R; Kuwabara T; Soga S; Akinaga S; Nara S; Kanda Y
    Bioorg Med Chem; 2007 Feb; 15(3):1363-82. PubMed ID: 17127066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.
    Dinsmore CJ; Bogusky MJ; Culberson JC; Bergman JM; Homnick CF; Zartman CB; Mosser SD; Schaber MD; Robinson RG; Koblan KS; Huber HE; Graham SL; Hartman GD; Huff JR; Williams TM
    J Am Chem Soc; 2001 Mar; 123(9):2107-8. PubMed ID: 11456854
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
    Trotter BW; Quigley AG; Lumma WC; Sisko JT; Walsh ES; Hamann CS; Robinson RG; Bhimnathwala H; Kolodin DG; Zheng W; Buser CA; Huber HE; Lobell RB; Kohl NE; Williams TM; Graham SL; Dinsmore CJ
    Bioorg Med Chem Lett; 2001 Apr; 11(7):865-9. PubMed ID: 11294379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents.
    Omer CA; Kohl NE
    Trends Pharmacol Sci; 1997 Nov; 18(11):437-44. PubMed ID: 9426472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring structure-activity relationships of tricyclic farnesyltransferase inhibitors using ECLiPS libraries.
    Rokosz LL; Huang CY; Reader JC; Stauffer TM; Southwick EC; Li G; Chelsky D; Baldwin JJ
    Comb Chem High Throughput Screen; 2006 Aug; 9(7):545-58. PubMed ID: 16925514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
    McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
    J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
    [No Abstract]   [Full Text] [Related]  

  • 29. N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.
    Williams TM; Bergman JM; Brashear K; Breslin MJ; Dinsmore CJ; Hutchinson JH; MacTough SC; Stump CA; Wei DD; Zartman CB; Bogusky MJ; Culberson JC; Buser-Doepner C; Davide J; Greenberg IB; Hamilton KA; Koblan KS; Kohl NE; Liu D; Lobell RB; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Huff JR
    J Med Chem; 1999 Sep; 42(19):3779-84. PubMed ID: 10508426
    [No Abstract]   [Full Text] [Related]  

  • 30. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
    Augeri DJ; O'Connor SJ; Janowick D; Szczepankiewicz B; Sullivan G; Larsen J; Kalvin D; Cohen J; Devine E; Zhang H; Cherian S; Saeed B; Ng SC; Rosenberg S
    J Med Chem; 1998 Oct; 41(22):4288-300. PubMed ID: 9784104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UCF116, new inhibitors of farnesyltransferase produced by Streptomyces.
    Hara M; Soga S; Itoh M; Shono K; Eishima J; Mizukami T
    J Antibiot (Tokyo); 2000 Jul; 53(7):720-3. PubMed ID: 10994815
    [No Abstract]   [Full Text] [Related]  

  • 32. 3-Imidazolylmethylaminophenylsulfonyltetrahydroquinolines, a novel series of farnesyltransferase inhibitors.
    Ding CZ; Hunt JT; Ricca C; Manne V
    Bioorg Med Chem Lett; 2000 Feb; 10(3):273-5. PubMed ID: 10698452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y; Vogt A; Sebti SM; Hamilton AD
    J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.
    Ohkanda J; Lockman JW; Yokoyama K; Gelb MH; Croft SL; Kendrick H; Harrell MI; Feagin JE; Blaskovich MA; Sebti SM; Hamilton AD
    Bioorg Med Chem Lett; 2001 Mar; 11(6):761-4. PubMed ID: 11277514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
    Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
    J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.
    Henry KJ; Wasicak J; Tasker AS; Cohen J; Ewing P; Mitten M; Larsen JJ; Kalvin DM; Swenson R; Ng SC; Saeed B; Cherian S; Sham H; Rosenberg SH
    J Med Chem; 1999 Nov; 42(23):4844-52. PubMed ID: 10579847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics.
    Qian Y; Vogt A; Vasudevan A; Sebti SM; Hamilton AD
    Bioorg Med Chem; 1998 Mar; 6(3):293-9. PubMed ID: 9568283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
    Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I.
    Carrico D; Blaskovich MA; Bucher CJ; Sebti SM; Hamilton AD
    Bioorg Med Chem; 2005 Feb; 13(3):677-88. PubMed ID: 15653335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.